Actively Recruiting
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)
Led by Suzhou Municipal Hospital · Updated on 2026-01-23
30
Participants Needed
4
Research Sites
134 weeks
Total Duration
On this page
Sponsors
S
Suzhou Municipal Hospital
Lead Sponsor
T
The Affiliated Jiangning Hospital of Nanjing Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This seamless two-stage phase II/III clinical trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension. Stage 1 is a phase II, multicenter, open-label, randomized trial to determine the optimal treatment strategy. Stage 2 is a phase III, multicenter, randomized, double-blind trial investigating the efficacy and safety of optimal treatment strategy compared to sham control.
CONDITIONS
Official Title
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individual with office systolic blood pressure (SBP) ≥ 140 mmHg and <160 mmHg, and office diastolic blood pressure (DBP)<100mmHg after standardized antihypertensive drug treatment for 1 month;
- Individual with 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average systolic blood pressure (ASBP) ≥130 mmHg；
- The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm；
- Individual is willing to sign the informed consent of the study.
You will not qualify if you...
- Individual diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome)；
- Individuals with ≥ 3 cardiovascular risk factors (male>55 years old, female>65 years old; smoking or passive smoking; 2-hour postprandial blood glucose 7.8-11mmol/L and/or impaired fasting glucose (6.1-6.9mmol/L); LDL-C ≥ 3.4mmol/L (130mg/dl), HDL-C<1.0mmol/L (40mg/dl) or TC ≥ 5.2mmol/L (200mg/dl); Family history of early onset of cardiovascular disease, age of onset of first degree relatives<50 years old; Abdominal obesity, waist circumference: male>90cm, female>85cm or BMI>28kg/m2) or hypertensive target organ damage;
- riser hypertension (defined as night blood pressure higher than daytime blood pressure by ABPM)
- Regular night shift workers
- Individuals taking other medications that may affect blood pressure (such as glucocorticoids);
- Individual with history of kidney or kidney surrounding tissue surgery;
- Individuals with impairment of liver or kidney function (ALT, AST or creatinine greater than 2 times of the upper limit of normal reference);
- Individual with myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment;
- Individual with type 1 diabetes or uncontrolled type 2 diabetes；
- Individual with uncontrolled thyroid dysfunction;
- Individual with urinary calculi or hematuria；
- Individual with atrial fibrillation;
- Individual with severe structural heart disease (e.g. valvular heart disease, cardiomyopathy, congenital heart disease);
- Individual with second degree and above atrioventricular block and/or sick sinus syndrome;
- Individual with abnormal coagulation function;
- Individual with infected waist skin;
- Individual with claustrophobia；
- Individual with malignant tumor;
- History of allergy to amlodipine, olmesartan, and hydrochlorothiazide
- Individual is pregnant, nursing or planning to be pregnant;
- Individual is unwilling to sign informed consent;
- Individual fails to complete the screening period.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
The Affiliated Jiangning Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210000
Actively Recruiting
2
The first Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210000
Actively Recruiting
3
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China, 210000
Actively Recruiting
4
Suzhou Municipal Hospital
Suzhou, Jiangsu, China, 210000
Actively Recruiting
Research Team
Y
Yanhui Sheng
CONTACT
Y
Yang Hua
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here